Our collaborator Dr Chris Jones and his fantastic team at The Institute of Cancer Research were profiled in The Observer for their work on DIPG with support from Abbie's Army. M4K Pharma is proud to be working with them to bring an affordable DIPG cure to patients.
Study published on new drug class targeting ACVR1 mutation for DIPG Scientists at The Institute of Cancer Research, London, along with colleagues at the Structural Genomics Consortium in Oxford, have published their findings on a new drug class that can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumours in mice. Mutated versions [...]
Richard Gold (McGill University) and Max Morgan (SGC, M4k Pharma) penned an opinion piece in the Globe and Mail discussing how open science projects with no patents can result in local economic development, citing the recent $1Billion investment deal that Celgene signed with the Ontario Institute for Cancer Research (OICR) and their commercialization arm FACIT [...]
Can an open drug discovery model find a solution for rare brain cancers in children? Dr. Aled Edwards OICR-funded drug discovery project’s unique ‘open science’ business model is accelerating the search for a solution to lethal pediatric brain cancers. Diffuse intrinsic pontine glioma (DIPG) is a lethal and inoperable brain cancer with a median survival [...]
Reaction Biology Joins the Fight Against DIPG with M4K Pharma [News Release] Malvern, PA- May 23, 2018. Reaction Biology Corporation (“RBC”), a leading contract research organization providing early stage drug discovery services, announced that it has partnered with M4K Pharma (“M4K”), an open science drug discovery and development company, in the fight against diffuse [...]
[Podcast] Bio2040 interviews M4K Pharma's Owen Roberts In a podcast interview with Bio2040, CEO Owen Roberts discusses M4K Pharma's business model and why open science and sharing can be the path to finding medicines for rare diseases like DIPG.
Editorial: Research community ready for Open Source Drug Discovery In an Editorial to the Canadian Science Policy Centre, Drs. Aled Edwards and Aidan Hollis describe the need for Open Source Drug Discovery to address the inefficiencies in developing new drugs and the resulting exorbitant prices of new medicines. The support for M4K [...]
OICR’s Cancer Therapeutics Innovation Pipeline initiative funds M4K’s ALK2 program for DIPG as part of the inaugural set of projects
OICR's Cancer Therapeutics Innovation Pipeline initiative funds M4K's ALK2 program for DIPG as part of the inaugural set of projects The Ontario Institute for Cancer Research (OICR) announced its Cancer Therapeutics Innovation Pipeline (CTIP) initiative and the first 10 projects selected for the inaugural round of funding. CTIP will support the [...]
Making medicine, not money: How one U of T researcher's startup is rethinking Big Pharma's business model M4K Pharma's first target is a rare childhood brain cancer that's just as deadly as it was 50 years ago From U of T News (November 3, 2017) The latest medical innovation to [...]